FXIII deficient patients benefit from a plasma concentrate with a long-lasting efficacy and safety record. A phase III clinical trial has recently been completed with a recombinant FXIII which has been proven to be safe and effective in preventing bleeding episodes in patients with congenital FXIII-A subunit deficiency [27]. In future, patients with RBD could take advantage of the many bioengineering as well as alternative strategies (aptamers, RNAi, inhibition

of TFPI, etc.), which are under development for persons with haemophilia [28]. Midori Shima has received honoraria as a consultant for his Selleckchem NVP-LDE225 active participation in advisory boards of Chugai Pharmaceutical Company, The Chemo-Sero-Therapeutic Research Institute, Bayer, Baxter, Biogen Idec, CSL Behring, Pfizer, Novo Nordisk. He has received research grants from Bayer, Baxter, Pfizer, Novo Nordisk, Chugai Pharmaceutical Company, Japan Blood Products Organization. Cedric Hermans has received honoraria as a consultant or for his active

participation in advisory selleck compound boards organized by Baxter, Bayer, Pfizer, CAF-DCF, SOBI, Ipsen, LFB, CSL Behring, Novo Nordisk, and Octapharma. He has received research grants or lecture chairs from Baxter, Bayer, Pfizer, CAF-DCF, CSL Behring, Novo Nordisk, Octapharma, and Ipsen. P de Moerloose has received honoraria as a consultant or for his active participation in advisory boards organized by Baxter, Bayer and LFB and has received research grants

or lecture chairs from Baxter, Bayer, CSL Behring, LFB and Novo Nordisk. “
“To compare the use of 740 Mbq (20 mCi) of 153Sm and 185 Mbq (5mCi) of 90Y, both labelling hydroxyapatite (HA), for knee synovectomy in haemophilic patients, 1 year after the intervention. Thirty three men (36 knees) were studied, divided into two groups: 1 – treatment using 740 Mbq of 153Sm-HA: 20 knees of 18 patients, with mean age of 21.4 ± 13.3 years (ranging from 7 to 56 years) and mean Pettersson score of 5.3; 2 – treatment using 185 Mbq of 90Y-HA: 16 knees of 15 patients, with mean age of 26.3 ± 10.3 (ranging from 7 to 51 years) and Carbohydrate mean Pettersson score of 6.3. The following criteria were adopted for the evaluation before and 1 year after synovectomy: reduction in haemarthrosis episodes and pain using a visual analogue scale, as well as improved joint mobility. The occurrence of adverse events in the treatment was also considered. The chi-square, Wilcoxon and Mann–Whitney tests were used with P ≤ 0.05 set as significant. The occurrence of haemarthrosis declined by 65.7% with the use of 153Sm-HA and 82.6% for 90Y-HA, with no statistical difference between the groups (P = 0.632); pain reduction was 42.5% in group 1 and 30.7% in group 2, once again with no statistical difference (P = 0.637). Improvement in joint mobility was not significant for both groups.